Company Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives.
The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions.
The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases.
It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins.
The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices.
The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals.
The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products.
Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions.
The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems.
Grifols, S.A. has a technology collaboration agreement with Mondragon.
The company was founded in 1940 and is headquartered in Barcelona, Spain.
Country | ES |
IPO Date | Jun 2, 2011 |
Industry | Drug Manufacturers - General |
Sector | Healthcare |
Employees | 23,000 |
CEO | Jose Ignacio Abia Buenache |
Contact Details
Address: Avinguda de la Generalitat, 152 Barcelona, ES | |
Website | https://www.grifols.com |
Stock Details
Ticker Symbol | GRFS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001438569 |
CUSIP Number | 398438408 |
ISIN Number | US3984384087 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Jose Ignacio Abia Buenache | Chief Executive Officer & Director |
Alfredo Arroyo Guerra CPA | Chief Financial Officer & Vice President |
Lluis Pons Gomez | Senior Vice President of Strategy & Chief Operating Officer Office |
Camille Alpi | Chief Human Resources & Talent Officer |
David Ian Bell | Chief Corporate Development, Legal & Data Protection Officer |
Maria Teresa-Rioné Llano | Chief Communications Officer |
Nuria Pascual Lapeña | Vice President of Corporate Treasury, Risk Management Investor Relation & Sustainability Officer |
Sergio Roura Adell | President of Commercial Tech Support |
Vicente Blanquer Torre | Chief Quality Officer |
Víctor Grifols Deu | Executive Director |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 11, 2024 | 6-K | Filing |
Dec 09, 2024 | 6-K | Filing |
Nov 27, 2024 | 6-K | Filing |
Nov 19, 2024 | 6-K | Filing |
Nov 19, 2024 | 6-K | Filing |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 07, 2024 | 6-K | Filing |
Sep 25, 2024 | 6-K | Filing |
Sep 23, 2024 | 6-K | Filing |
Jul 30, 2024 | 6-K | Filing |